Le Lézard
Classified in: Health, Science and technology
Subject: Share Issue

Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)


As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) ("Twist" or the "Company"), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it has granted a total of 122,400 restricted stock units ("RSUs") to 36 recently hired individuals as an inducement material to their acceptance of employment with Twist. The employment inducement awards were granted under Twist's Inducement Equity Incentive Plan and related form of restricted stock award agreement in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Twist, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with Twist, pursuant to Nasdaq Listing Rule 5635(c)(4).

The RSUs vest over a 48-month period for each employee as follows: 25% vests on the one year anniversary of the start date of the employee (the "Vesting Commencement Date"), and 1/16 of the RSUs vest on each quarterly anniversary (or the last day of the month if no such day exists) of the Vesting Commencement Date thereafter, subject to the employee's continued service through each vesting date.

About Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by "writing" DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.


These press releases may also interest you

at 15:03
The following is a statement by National Press Club President Emily Wilkins on the 2024 recipient of the President's Award to be presented at the National Press Club Awards Dinner on August 28....

at 14:41
In response to the April 29th U.S. Food & Drug Administration (FDA) Final Rule 21 CFR Part 809 Medical Devices: Laboratory Developed Tests (LDTs), Orchard Software is actively working alongside its customers to fully understand the implications and...

at 14:30
CodePR, a boutique communications agency amplifying the brands of VC firms and innovative startups, today announced that Tim Turpin, former Sparkpr Executive Vice President and head of its Venture Capital and Emerging Technologies Practice, has...

at 14:07
  Mullen Group Ltd. ("Mullen Group", "We", "Our" and/or the "Corporation") is pleased to announce the closing of the previously announced acquisition of ContainerWorld Forwarding Services Inc. and its operating subsidiaries ("ContainerWorld")...

at 14:07
ONLC Training extends its schedule of live Copilot courses. By continuing its free Copilot Adoption Planning Classes through 2024, ONLC demonstrates its commitment to helping organizations plan for Microsoft Copilot. The live, instructor-led classes...

at 14:05
GuidePoint Security, a cybersecurity solutions leader enabling organizations to make smarter decisions and minimize risk, announced today the appointment of Rachel Haag as the company's Chief Marketing Officer (CMO). Haag will oversee GuidePoint's...



News published on and distributed by: